Ilya Rozenberg
Psychiatric/Mental Health · Glen Burnie, MDNPI 1467460865
Payments from drug & device makers
Across 1,586 payments — averaging $360.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$128K
- AbbVie$104K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$95K
- E.r. Squibb & Sons, L.L.C.$61K
- Alkermes, Inc.$52K
- Neurocrine Biosciences, Inc.$51K
- plus $81K from 28 others
What the payments were for
- Consulting fees$42,0927%
- Speaking & faculty fees$462,51281%
- Travel & lodging$38,6347%
- Food & beverage$28,2665%
- Education$2380%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$197,694
- INVEGA SUSTENNA$124,598
- INVEGA TRINZA$114,458
- VRAYLAR$97,085
- CAPLYTA$90,879
- INGREZZA$48,535
- COBENFY$44,198
- UZEDY$37,449
- REXULTI$19,779
- Austedo XR$8,976
- Fanapt$5,743
- ARISTADA$1,170
- ARISTADA INITIO$119
How this compares
$571,742 in reported general payments places this provider in the 95th percentile of 1,461 psychiatric/mental health providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 229 | $717,570 |
| IngrezzaValbenazine Tosylate | 76 | $619,955 |
| Invega TrinzaPaliperidone Palmitate | 39 | $318,102 |
| VraylarCariprazine Hcl | 88 | $137,567 |
| TrintellixVortioxetine Hydrobromide | 206 | $115,542 |
| NamzaricMemantine Hcl/Donepezil Hcl | 111 | $71,987 |
| Lupron DepotLeuprolide Acetate | 14 | $61,586 |
| Abilify MaintenaAripiprazole | 20 | $57,468 |
| RexultiBrexpiprazole | 34 | $56,671 |
| CaplytaLumateperone Tosylate | 28 | $52,351 |
| Aripiprazole | 374 | $29,559 |
| Doxepin Hcl | 174 | $28,208 |
| BelsomraSuvorexant | 49 | $21,767 |
| VyvanseLisdexamfetamine Dimesylate | 58 | $21,349 |
| SecuadoAsenapine | 13 | $19,273 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $128,449 | $1,035,672268 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $50,736 | $619,95576 claims |
| AbbVieVraylar, Namzaric, Lupron Depot | $104,204 | $271,139213 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $423 | $136,891264 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $20,864 | $114,13954 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $94,859 | $52,35128 claims |
| Almatica Pharma LLCSertraline Hcl, Loreev Xr | $149 | $22,4531,061 claims |
| MerckBelsomra | $236 | $21,76749 claims |
| Eisai Inc.Dayvigo | $118 | $12,04834 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,461 psychiatric/mental health providers in Maryland.
Other psychiatric/mental health in Glen Burnie
- Travis BairdGlen Burnie$11K
- Ololade AdekoyaGlen Burnie$6K
- Mary Ogunlowo-OmobhudeGlen Burnie$5K
- Hara OyedejiOwings Mills$780K
- Michelle WilliamsColumbia$158K
- Kristin ClemensGaithersburg$36K
- Antonio HeroldHavre de Grace$23K
- Paul KlaverweidenFruitland$17K
- Margaret WebbAberdeen$16K
- Susan KrausTowson$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.